Mulmit

EXELIXIS, INC.EXELIXIS, INC.

EXEL Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2026-01-022,320,126,000872,191,000782,600,0002.78
2025-01-032,168,701,000604,617,000521,300,0001.76
2023-12-291,830,208,000170,885,000207,800,0000.65
2022-12-301,611,062,000201,484,000182,300,0000.56
2021-12-311,434,970,000286,666,000231,100,0000.72

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-08-10Beckerle Mary C9,812
2026-06-01WYSZOMIERSKI JACK L3,925
2026-06-01Eckhardt Sue Gail9,812
2026-05-27PAPADOPOULOS STELIOS8,367
2026-05-27Heyman Tomas J.8,367
2026-05-27Eckhardt Sue Gail8,367
2026-05-27Smith Julie8,367
2026-05-27Freire Maria C8,367
2026-05-27Beckerle Mary C8,367
2026-05-27Oliver Bob8,367
2026-05-27WYSZOMIERSKI JACK L8,367
2026-05-27POSTE GEORGE8,367

8-K events

FiledItems
2026-08-31Other events
2026-08-05Results of operations · Financial statements and exhibits
2026-05-29Officer or director change · Submission of matters to a vote · Financial statements and exhibits
2026-05-05Results of operations · Other events · Financial statements and exhibits
2026-02-10Results of operations · Financial statements and exhibits
2026-01-12Results of operations · Financial statements and exhibits
2025-11-07Officer or director change · Other events
2025-11-04Results of operations · Other events · Financial statements and exhibits
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

Biological Products, (No Diagnostic Substances) — 같은 업종, 그리고 규모가 비슷한 기업Biological Products, (No Diagnostic Substances) — and other companies of a similar size

SEC가 같은 업종(Biological Products, (No Diagnostic Substances))으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (Biological Products, (No Diagnostic Substances)) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.